CRL

Business Profile & Competitive Position

Charles River Laboratories International, Inc. sits in the Healthcare sector, specifically the Medical - Diagnostics & Research industry. The company describes itself as a full-service, non-clinical drug-development partner. Its work spans research-model technologies, discovery and safety-assessment services (both GLP and non-GLP), and manufacturing support products and services that help move a therapy from target identification through non-clinical development and product release.

Operationally, the business is split into three reportable segments. In 2025, total revenue was $4.0 billion, with Discovery and Safety Assessment (DSA) contributing 59.8%, Research Models and Services (RMS) contributing 21.1%, and Manufacturing Solutions contributing 19.1%. The company runs more than 120 sites across more than 20 countries.

The reported margin and return figures, however, do not paint a picture of a currently entrenched, wide-moat operator. Net margin is negative 6.0% and ROE is negative 7.7%. Those numbers alone say the business is not converting revenue into profit or generating positive equity returns right now. A strong competitive moat would normally show stronger, consistently positive margins and returns on equity. Instead, these metrics suggest either pricing pressure, elevated operating or integration costs, or a revenue mix that is not yet scaling efficiently. The large DSA segment—now being reorganized into one combined organization—appears central to whether the company can rebuild sustainable profitability.

Financial Posture

Charles River Laboratories carries a market capitalization of $14.5 billion. The current P/E ratio is negative 62.1, which is consistent with a company reporting losses; trailing earnings are negative, so the multiple is not a useful valuation gauge on its own. With net margin at negative 6.0%, the company is burning a small amount of bottom-line profit on every dollar of revenue, and the negative ROE of 7.7% means common equity is currently being eroded rather than compounded.

The stock's beta is 1.40, meaning it has tended to move roughly 40% more than the broad market in either direction. At the October 12, 2026 snapshot, the price was $300.42, the RSI stood at 57.8, and the 50-day exponential moving average was $278.44. That places the stock above its intermediate moving average with a neutral-to-warm momentum read, but the underlying fundamentals still show a business in repair mode rather than one firing on all cylinders.

Strategic Priorities & Outlook

According to the company's most recent 10-K, management is focused on integrating Discovery Services and Safety Assessment into a single DSA organization with a combined sales force and leadership structure. The goal is to present a comprehensive, integrated scientific portfolio and position Charles River as the "scientific partner of choice" to accelerate biomedical research and therapeutic innovation.

At the same time, the company is actively reshaping its footprint. It plans to close or consolidate roughly 12 additional sites over the next two years, mainly in DSA and RMS. Those moves are aimed at improving efficiency, though they also carry execution risk with client transitions and restructuring charges. On the growth side, Charles River is seeking to expand its Biologics Testing Solutions service offerings and facilities in the U.S. and Europe. In January 2026, it acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. That acquisition also underscores the company's reliance on live and specialized research models.

Macro & Geopolitical Exposure

As a Medical - Diagnostics & Research company with a global footprint, Charles River Laboratories is exposed to several macro and geopolitical vectors. First, regulation: GLP and non-GLP safety studies are governed by strict FDA, EMA, and other health-authority standards. Any tightening of animal-welfare rules or changes to non-human-primate import requirements could directly affect research-model supply and safety-assessment workflows.

Second, currency and trade risk: with more than 120 sites across more than 20 countries, revenue and costs can move on foreign-exchange swings, and cross-border shipments of reagents, models, and biological materials face customs and tariff regimes. Third, the broader biotech funding environment matters: when venture and public biotech funding is plentiful, demand for discovery and safety-assessment services tends to rise; when capital tightens, smaller clients defer studies or negotiate harder on price. Finally, supply-chain reliability for specialized research models and laboratory consumables is a persistent operational sensitivity for the diagnostics-and-research industry.

Recent Developments

The most recent news flow has been constructive. On October 9, 2026, Charles River Laboratories announced it would release third-quarter 2026 results and hold a conference call, according to BusinessWire. On October 6, 2026, also via BusinessWire, it said it had partnered with Autolomous to transform laboratory execution systems, a move aligned with its broader push to integrate and digitize DSA workflows.

Two Zacks articles on October 7, 2026, framed the stock's recent strength. One asked whether PGNY or CRL is the better value stock right now, while the other noted Charles River had gained 75.8% over the prior year and explored what was driving the rally. These headlines reflect a market narrative focused on turnaround execution and relative valuation after a period of recovery, but they do not change the fundamental fact that trailing margins and returns remain negative.

Earnings Behavior & Post-Earnings Drift

Charles River Laboratories has beaten earnings estimates in all of the last eight reported quarters, for a 100% beat rate, with an average earnings surprise of 9.3%. Despite that consistency, the stock's short-term reaction has been uneven.

Looking at the trailing four reports chronologically, the November 5, 2025 release delivered EPS of $2.43 against an estimate of $2.32, a 4.7% beat, with the stock rising 1.9% the next day and 2.27% over the following five sessions. The February 18, 2026 report produced EPS of $2.39 versus $2.33, a 2.6% beat, with a one-day gain of 3.95% and a five-day gain of 6.05%. The May 7, 2026 quarter showed EPS of $2.06 versus $1.96, a 5.1% beat, but the stock fell 2.23% the next day and dropped 12.42% over the following five sessions. The most recent report, on August 5, 2026, delivered EPS of $3.02 against $2.74, a 10.2% beat, with the stock up 1.84% the next day and 9.07% over the following five sessions.

Averaged across the last eight quarters, the five-day post-earnings drift has been 1.24% and is classified as "up." That mild upward drift masks meaningful quarter-to-quarter dispersion, so the beat itself has not guaranteed a positive price reaction. The next scheduled report is November 4, 2026, before the open, with an official consensus EPS estimate of $2.97.

If you want a fuller picture of how institutional analysts are interpreting the turnaround plan, the valuation disconnect, and the setup into the November 4 report, look for the full institutional verdict on CRL.